These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26164165)

  • 1. Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy: Comparison of the Prognostic Ability of RECIST 1.1, an Alternate Method (Crabb), and Image Heterogeneity Analysis.
    Yip C; Tacelli N; Remy-Jardin M; Scherpereel A; Cortot A; Lafitte JJ; Wallyn F; Remy J; Bassett P; Siddique M; Cook GJ; Landau DB; Goh V
    J Thorac Imaging; 2015 Sep; 30(5):300-7. PubMed ID: 26164165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria.
    Lee HY; Lee KS; Hwang HS; Lee JW; Ahn MJ; Park K; Kim TS; Yi CA; Chung MJ
    Korean J Radiol; 2010; 11(6):618-26. PubMed ID: 21076587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (99m)Tc-3PRGD 2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab.
    Ma Q; Min K; Wang T; Chen B; Wen Q; Wang F; Ji T; Gao S
    Ann Nucl Med; 2015 Jul; 29(6):519-27. PubMed ID: 25911312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response?
    Kim YN; Lee HY; Lee KS; Seo JB; Chung MJ; Ahn MJ; Park K; Kim TS; Yi CA
    Korean J Radiol; 2012; 13(6):702-10. PubMed ID: 23118568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
    J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy.
    Tacelli N; Santangelo T; Scherpereel A; Duhamel A; Deken V; Klotz E; Cortot A; Lafitte JJ; Wallyn F; Remy J; Remy-Jardin M
    Eur Radiol; 2013 Aug; 23(8):2127-36. PubMed ID: 23553586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
    Lind JS; Meijerink MR; Dingemans AM; van Kuijk C; Ollers MC; de Ruysscher D; Postmus PE; Smit EF
    Eur Radiol; 2010 Dec; 20(12):2890-8. PubMed ID: 20625738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (99m)Tc-3P-RGD2 SPECT to monitor early response to bevacizumab therapy in patients with advanced non-small cell lung cancer.
    Chen B; Zhao G; Ma Q; Ji B; Ji T; Xin H; Gao S
    Int J Clin Exp Pathol; 2015; 8(12):16064-72. PubMed ID: 26884883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
    de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-tumour CT-perfusion of unresectable lung cancer for the monitoring of anti-angiogenetic chemotherapy effects.
    Fraioli F; Anzidei M; Serra G; Liberali S; Fiorelli A; Zaccagna F; Longo F; Anile M; Catalano C
    Br J Radiol; 2013 Sep; 86(1029):20120174. PubMed ID: 23908346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis.
    Cook GJ; O'Brien ME; Siddique M; Chicklore S; Loi HY; Sharma B; Punwani R; Bassett P; Goh V; Chua S
    Radiology; 2015 Sep; 276(3):883-93. PubMed ID: 25897473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria.
    Chung WS; Park MS; Shin SJ; Baek SE; Kim YE; Choi JY; Kim MJ
    AJR Am J Roentgenol; 2012 Oct; 199(4):809-15. PubMed ID: 22997372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semiautomatic Analysis on Computed Tomography in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Reproducibility and Prognostic Significance of Unidimensional and 3-dimensional Measurements.
    Colombi D; Manna C; Montermini I; Seletti V; Diciotti S; Tiseo M; Fontana E; De Filippo M; Silva M; Sverzellati N
    J Thorac Imaging; 2015 Sep; 30(5):290-9. PubMed ID: 25837590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of clinical outcomes of antiangiogenic-targeted therapy in patients with pulmonary metastatic renal cell carcinoma using non-contrast-enhanced computed tomography.
    Wu GY; Suo ST; Kong W; Jin D; Zhang J; Xu JR
    Acad Radiol; 2014 Nov; 21(11):1434-40. PubMed ID: 25097010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.
    Nishino M; Cryer SK; Okajima Y; Sholl LM; Hatabu H; Rabin MS; Jackman DM; Johnson BE
    Cancer Imaging; 2012 Jun; 12(1):225-35. PubMed ID: 22743083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience.
    Fraioli F; Anzidei M; Zaccagna F; Mennini ML; Serra G; Gori B; Longo F; Catalano C; Passariello R
    Radiology; 2011 May; 259(2):574-82. PubMed ID: 21357523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of metabolic and anatomic response to chemotherapy based on PERCIST and RECIST in patients with advanced stage non-small cell lung cancer.
    Ordu C; Selcuk NA; Akosman C; Eren OO; Altunok EC; Toklu T; Oyan B
    Asian Pac J Cancer Prev; 2015; 16(1):321-6. PubMed ID: 25640373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
    Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E
    Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
    Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
    Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.